DefiniGEN

DefiniGEN creates human cell models to support drug discovery and preclinical research.

Cambridge, UK—Founded 2018

£4.8MTotal raised

DefiniGEN provides human cell products and services, creating predictive disease cell models for preclinical research and drug development.

Marcus Yeo

CEO

Other26 November 2020

£3.3M

BGF led the round with participation from 24Haymarket to support US expansion and site growth.

29 June 2016

£1.5M

The follow-on investment will fund the commercial launch of new pancreatic and lung stem cell products.